Mark Halvorson

Array ( [id] => 14534565 [patent_doc_number] => 20190202904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => SYNTHETIC ANTIBODIES AGAINST VEGF AND THEIR USES [patent_app_type] => utility [patent_app_number] => 16/331512 [patent_app_country] => US [patent_app_date] => 2017-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16331512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13987139 [patent_doc_number] => 20190062727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => CANCER TREATMENT THROUGH RLIP76 PARTIAL DEPELETION [patent_app_type] => utility [patent_app_number] => 15/684508 [patent_app_country] => US [patent_app_date] => 2017-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12436 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15684508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12728755 [patent_doc_number] => 20180134752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => PAR1 AND PAR2 C-TAIL PEPTIDES AND PEPTIDE MIMETICS [patent_app_type] => utility [patent_app_number] => 15/682057 [patent_app_country] => US [patent_app_date] => 2017-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15682057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16260006 [patent_doc_number] => 10751415 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof [patent_app_type] => utility [patent_app_number] => 15/680187 [patent_app_country] => US [patent_app_date] => 2017-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 143 [patent_figures_cnt] => 250 [patent_no_of_words] => 63003 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15680187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314271 [patent_doc_number] => 20180208672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => ANTIBODIES SPECIFIC TO HETERODIMERS OF BCL-2 FAMILY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/677795 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15677795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17207762 [patent_doc_number] => 11168121 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Identification and use of novopeptides for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/669666 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 21 [patent_no_of_words] => 42470 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15669666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403757 [patent_doc_number] => 20190167722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => TRANSFECTION OF DENDRITIC CELLS AND METHODS THEREFOR [patent_app_type] => utility [patent_app_number] => 16/322310 [patent_app_country] => US [patent_app_date] => 2017-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12003479 [patent_doc_number] => 20170307635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'Method and a kit to quantify and qualify exosomes for diagnosis of prostate cancer and prostate hyperplasia' [patent_app_type] => utility [patent_app_number] => 15/644751 [patent_app_country] => US [patent_app_date] => 2017-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3674 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15644751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969906 [patent_doc_number] => 20170274058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'Cancer Stem Cell-Targeted Cancer Therapy' [patent_app_type] => utility [patent_app_number] => 15/619827 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85787 [patent_no_of_claims] => 121 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15619827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092575 [patent_doc_number] => 20170349666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AND PD-1 AXIS BINDING ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/600011 [patent_app_country] => US [patent_app_date] => 2017-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 76 [patent_no_of_words] => 99700 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15600011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866197 [patent_doc_number] => 20170233481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'ANTI-CD25 ANTIBODIES AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/585404 [patent_app_country] => US [patent_app_date] => 2017-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 35261 [patent_no_of_claims] => 85 [patent_no_of_ind_claims] => 44 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15585404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18201206 [patent_doc_number] => 11583577 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Cancer immunotherapy by immune activation or immune modulation via Globo series antigens [patent_app_type] => utility [patent_app_number] => 15/495470 [patent_app_country] => US [patent_app_date] => 2017-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 14133 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15495470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15119619 [patent_doc_number] => 20190346442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => IMPROVED HLA EPITOPE PREDICTION [patent_app_type] => utility [patent_app_number] => 16/094786 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16094786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12049889 [patent_doc_number] => 20170326232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'INTRATUMORAL ADMINISTRATION OF PARTICLES CONTAINING A TOLL-LIKE RECEPTOR 9 AGONIST AND A TUMOR ANTIGEN FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/488353 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 45024 [patent_no_of_claims] => 105 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15488353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836261 [patent_doc_number] => 20190276531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/093024 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16908990 [patent_doc_number] => 11041017 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Antibodies, pharmaceutical compositions and methods [patent_app_type] => utility [patent_app_number] => 15/473267 [patent_app_country] => US [patent_app_date] => 2017-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 45543 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15473267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12022250 [patent_doc_number] => 20170312349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'PEPTIDE CONJUGATED PARTICLES' [patent_app_type] => utility [patent_app_number] => 15/453807 [patent_app_country] => US [patent_app_date] => 2017-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 36931 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15453807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11707944 [patent_doc_number] => 20170176443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'METHOD FOR DETECTING OR MONITORING PROSTATE CANCER' [patent_app_type] => utility [patent_app_number] => 15/451061 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10035 [patent_no_of_claims] => 86 [patent_no_of_ind_claims] => 37 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971225 [patent_doc_number] => 20170275377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/448430 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 88 [patent_figures_cnt] => 88 [patent_no_of_words] => 89737 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15448430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13899051 [patent_doc_number] => 20190038730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => ENGINEERED CELLS & METHODS [patent_app_type] => utility [patent_app_number] => 16/076479 [patent_app_country] => US [patent_app_date] => 2017-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076479 [rel_patent_id] =>[rel_patent_doc_number] =>)